GILD trades 0.9% above Wall Street's consensus target of $150.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes GILD achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 58 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Gilead Sciences, Inc. (GILD) has a Wall Street consensus price target of $150.00, based on estimates from 58 covering analysts. With the stock currently trading at $151.37, this represents a potential downside of -0.9%. The company has a market capitalization of $187.94B.
Analyst price targets range from a low of $123.00 to a high of $175.00, representing a 35% spread in expectations. The median target of $150.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 39 analysts rating the stock as a Buy or Strong Buy,18 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, GILD trades at a trailing P/E of 22.3x. Analysts expect EPS to grow +83.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $150.23, with bear and bull scenarios of $94.64 and $197.94 respectively. Model confidence stands at 49/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ABBVAbbVie Inc. | $468.7B | $265.30 | $287.08 | +8.2% | Buy | 18.9x | 43 |
 BMYBristol-Myers Squibb Company | $124.9B | $61.15 | $70.00 | +14.5% | Buy | 8.8x | 42 |
 AMGNAmgen Inc. | $219.2B | $406.09 | $393.72 | -3.0% | Buy | 17.6x | 41 |
 BIIBBiogen Inc. | $33.6B | $227.53 | $245.88 | +8.1% | Buy | 18.3x | 49 |
 REGNRegeneron Pharmaceuticals, Inc. | $82.6B | $801.82 | $827.71 | +3.2% | Buy | 14.7x | 49 |
 VRTXVertex Pharmaceuticals Incorporated | $131.0B | $516.34 | $559.33 | +8.3% | Buy | 27.6x | 56 |
 MRKMerck & Co., Inc. | $365.8B | $148.11 | $158.12 | +6.8% | Buy | 53.9x | 38 |
 PFEPfizer Inc. | $160.6B | $28.17 | $28.50 | +1.2% | Hold | 9.5x | 39 |
 JNJJohnson & Johnson | $648.0B | $269.17 | $286.93 | +6.6% | Buy | 23.4x | 40 |
 INCYIncyte Corporation | $25.3B | $124.64 | $130.07 | +4.4% | Buy | 33.1x | 44 |
Quick answers to the most common questions about buying GILD stock.
Wall Street's consensus price target for GILD is $150, -0.9% from its current price of $151.37. The below-market target from 58 analysts suggests limited near-term appreciation.
GILD has a consensus rating of "Buy" based on 58 Wall Street analysts. The rating breakdown is predominantly bullish, with 39 Buy/Strong Buy ratings. The consensus 12-month price target of $150 implies -0.9% downside from current levels.
GILD's current price is $151.37 with a consensus target of $150 (-0.9% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $175 for GILD, while the most conservative target is $123. The consensus of $150 represents the median expectation. Our quantitative valuation model projects a bull case target of $198 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
GILD is heavily covered by Wall Street, with 58 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 39 have Buy ratings, 18 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GILD stock forecast based on 58 Wall Street analysts shows a consensus price target of $150, with estimates ranging from $123 (bear case) to $175 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $150, with bear/bull scenarios of $95/$198.
Our quantitative valuation model calculates GILD's fair value at $150 (base case), with a bear case of $95 and bull case of $198. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 49/100.
Analysts are cautious on GILD, with 1 Sell ratings and a price target of $150 (-0.9% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GILD analyst price targets range from $123 to $175, a 35% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $150 consensus represents the middle ground. Our model's $95-$198 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.